LGND
Ligand Pharmaceuticals Incorporated NASDAQ Listed Nov 18, 1992$210.31
Mkt Cap $4.2B
52w Low $98.89
75.0% of range
52w High $247.38
50d MA $213.08
200d MA $188.45
P/E (TTM)
35.3x
EV/EBITDA
20.4x
P/B
4.3x
Debt/Equity
0.4x
ROE
12.2%
P/FCF
74.8x
RSI (14)
—
ATR (14)
—
Beta
1.00
50d MA
$213.08
200d MA
$188.45
Avg Volume
217.6K
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
5980 Horton Street · Jupiter, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 232.55 | -11.8% | -9.6% | — | — | — | — | — |
| Feb 26, 2026 | AMC | 1.46 | 2.02 | +38.4% | 196.17 | +0.0% | +1.1% | +3.3% | +4.1% | +6.5% | +5.1% | — |
| Nov 6, 2025 | AMC | 1.97 | 3.09 | +56.9% | 208.22 | -1.3% | -2.8% | +0.5% | +0.2% | -1.3% | -3.3% | — |
| Aug 7, 2025 | AMC | 1.54 | 1.60 | +3.9% | 146.32 | +1.3% | +2.6% | +0.5% | +4.4% | +6.6% | +5.1% | — |
| May 8, 2025 | AMC | 1.30 | 1.33 | +2.3% | 102.51 | -0.4% | +1.9% | +3.8% | +3.0% | +2.5% | +0.9% | — |
| Feb 27, 2025 | AMC | 1.37 | -1.64 | -219.7% | 115.67 | +0.3% | +5.7% | -3.0% | -0.4% | -0.2% | +0.3% | — |
| Nov 7, 2024 | AMC | 0.75 | -0.39 | -152.0% | 129.90 | -2.8% | -6.7% | -5.0% | -7.1% | -6.0% | -11.1% | — |
| Aug 6, 2024 | AMC | 1.10 | 1.40 | +27.3% | 99.04 | +1.0% | -5.8% | -2.1% | +1.1% | +0.6% | +4.0% | — |
| May 7, 2024 | AMC | 1.13 | 1.20 | +6.2% | 73.22 | +1.6% | +9.8% | +17.6% | +19.2% | +14.8% | +16.5% | — |
| Feb 27, 2024 | AMC | 0.58 | 1.05 | +81.0% | 89.20 | -1.0% | -5.4% | -11.0% | -11.8% | -14.5% | -17.0% | — |
| Nov 8, 2023 | AMC | 0.68 | 1.02 | +50.0% | 52.23 | +5.3% | +4.6% | +6.0% | +5.6% | +8.1% | +8.1% | — |
| Aug 8, 2023 | AMC | 0.76 | 1.42 | +86.8% | 67.13 | +0.0% | +5.3% | +2.4% | +0.1% | +0.0% | +0.7% | — |
| May 4, 2023 | AMC | 0.89 | 2.28 | +156.2% | 76.71 | +4.3% | +3.4% | +1.0% | +1.5% | +1.1% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $241.79 | $243.66 | +0.8% | -3.9% | -7.0% | -5.1% | -5.9% | -5.6% |
| Apr 15 | Citigroup | Maintains | Buy → Buy | — | $232.34 | $230.43 | -0.8% | -3.1% | -3.9% | -0.2% | -0.2% | -2.4% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $213.44 | $220.00 | +3.1% | +8.9% | +5.5% | +4.6% | +8.6% | +8.6% |
| Mar 24 | Citigroup | Maintains | Buy → Buy | — | $200.36 | $200.88 | +0.3% | +0.6% | +2.1% | +1.7% | -2.4% | -3.9% |
| Feb 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $196.17 | $196.17 | +0.0% | +1.1% | +3.3% | +4.1% | +6.5% | +5.1% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $183.65 | $187.00 | +1.8% | +2.9% | +4.2% | +6.8% | +8.0% | +10.3% |
| Dec 10 | RBC Capital | Maintains | Outperform → Outperform | — | $185.83 | $187.77 | +1.0% | -1.0% | -1.5% | +2.0% | +3.8% | +3.7% |
| Dec 10 | Stifel | Maintains | Buy → Buy | — | $185.83 | $187.77 | +1.0% | -1.0% | -1.5% | +2.0% | +3.8% | +3.7% |
| Nov 10 | RBC Capital | Maintains | Outperform → Outperform | — | $202.48 | $204.44 | +1.0% | +3.4% | +3.1% | +1.5% | -0.6% | -0.8% |
| Nov 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $208.22 | $205.45 | -1.3% | -2.8% | +0.5% | +0.2% | -1.3% | -3.3% |
| Nov 7 | Benchmark | Maintains | Buy → Buy | — | $208.22 | $205.45 | -1.3% | -2.8% | +0.5% | +0.2% | -1.3% | -3.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $190.38 | $196.00 | +3.0% | +9.4% | +6.4% | +9.9% | +9.6% | +8.0% |
| Nov 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $191.31 | $192.97 | +0.9% | -0.0% | -1.0% | -0.5% | +8.8% | +5.8% |
| Sep 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $163.73 | $164.40 | +0.4% | +1.7% | +2.4% | +1.8% | +1.3% | +1.0% |
| Sep 2 | Benchmark | Maintains | Buy → Buy | — | $161.71 | $161.71 | +0.0% | +1.2% | +3.0% | +3.7% | +3.1% | +2.6% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $159.10 | $158.40 | -0.4% | +0.5% | +1.6% | +2.9% | +4.7% | +5.4% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $146.32 | $148.26 | +1.3% | +2.6% | +0.5% | +4.4% | +6.6% | +5.1% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $142.40 | $144.80 | +1.7% | +2.8% | +5.4% | +3.2% | +7.2% | +9.6% |
| Jul 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $131.58 | $133.85 | +1.7% | +2.8% | +0.0% | +0.9% | +2.9% | +2.7% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $102.51 | $102.08 | -0.4% | +1.9% | +3.8% | +3.0% | +2.5% | +0.9% |
| Dec 23 | Benchmark | Maintains | Buy → Buy | — | $114.64 | $114.59 | -0.0% | -0.7% | -1.1% | -0.3% | -4.8% | -7.7% |
| Dec 16 | Barclays | Maintains | Overweight → Overweight | — | $116.91 | $117.30 | +0.3% | +4.6% | +3.0% | -2.1% | -2.5% | -1.9% |
| Dec 11 | RBC Capital | Maintains | Outperform → Outperform | — | $118.60 | $121.18 | +2.2% | +1.5% | -4.3% | -1.4% | +3.2% | +1.5% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $118.60 | $121.18 | +2.2% | +1.5% | -4.3% | -1.4% | +3.2% | +1.5% |
| Nov 12 | RBC Capital | Maintains | Outperform → Outperform | — | $123.47 | $123.08 | -0.3% | -2.2% | -1.1% | -6.5% | -9.5% | -9.6% |
| Nov 8 | Barclays | Maintains | Overweight → Overweight | — | $129.90 | $126.27 | -2.8% | -6.7% | -5.0% | -7.1% | -6.0% | -11.1% |
| Nov 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $129.90 | $126.27 | -2.8% | -6.7% | -5.0% | -7.1% | -6.0% | -11.1% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $129.90 | $126.27 | -2.8% | -6.7% | -5.0% | -7.1% | -6.0% | -11.1% |
| Nov 8 | Benchmark | Maintains | Buy → Buy | — | $129.90 | $126.27 | -2.8% | -6.7% | -5.0% | -7.1% | -6.0% | -11.1% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $109.81 | $109.56 | -0.2% | -3.7% | +0.2% | +0.4% | +1.2% | +6.5% |
| Oct 28 | Barclays | Maintains | Overweight → Overweight | — | $111.82 | $113.26 | +1.3% | +1.4% | +3.3% | -1.8% | -5.5% | -1.6% |
| Oct 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $106.39 | $106.83 | +0.4% | +0.4% | +0.1% | +0.5% | +4.3% | +5.1% |
| Aug 12 | RBC Capital | Maintains | Outperform → Outperform | — | $100.16 | $103.28 | +3.1% | -0.6% | +2.9% | +0.9% | +3.0% | +2.0% |
| Aug 12 | Benchmark | Maintains | Buy → Buy | — | $100.16 | $103.28 | +3.1% | -0.6% | +2.9% | +0.9% | +3.0% | +2.0% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $93.32 | $93.59 | +0.3% | +3.9% | +7.3% | +6.7% | +10.4% | +8.3% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $99.04 | $100.00 | +1.0% | -5.8% | -2.1% | +1.1% | +0.6% | +4.0% |
| Jul 9 | Craig-Hallum | Maintains | Buy → Buy | — | $86.88 | $87.78 | +1.0% | +5.6% | +10.8% | +12.8% | +14.4% | +11.3% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $84.37 | $85.89 | +1.8% | +3.0% | +8.7% | +14.1% | +16.2% | +17.8% |
| Jun 28 | Benchmark | Maintains | Buy → Buy | — | $82.33 | $82.72 | +0.5% | +2.3% | +3.1% | +3.0% | +0.4% | +2.5% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $77.82 | $78.45 | +0.8% | +5.8% | +8.3% | +9.0% | +9.0% | +6.3% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.22 | $74.37 | +1.6% | +9.8% | +17.6% | +19.2% | +14.8% | +16.5% |
| Apr 12 | Benchmark | Maintains | Buy → Buy | — | $81.43 | $81.48 | +0.1% | -0.1% | -2.0% | -1.9% | -3.1% | -10.9% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $84.35 | $85.06 | +0.8% | -5.9% | -6.7% | -9.6% | -12.3% | -13.8% |
| Dec 13 | Benchmark | Maintains | Buy → Buy | — | $62.94 | $63.12 | +0.3% | +6.9% | +7.6% | +7.0% | +9.9% | +11.6% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.56 | $62.88 | +0.5% | +1.2% | -2.4% | -5.2% | -5.6% | -5.9% |
| Aug 23 | Benchmark | Maintains | Buy → Buy | — | $66.40 | $67.44 | +1.6% | +1.2% | -0.5% | -1.5% | -2.2% | -3.1% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.13 | $67.13 | +0.0% | +5.3% | +2.4% | +0.1% | +0.0% | +0.7% |
| Jul 25 | Barclays | Maintains | Overweight → Overweight | — | $66.56 | $66.34 | -0.3% | +1.1% | +1.7% | +1.3% | +2.2% | +0.6% |
| Jun 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $71.20 | $72.00 | +1.1% | +5.8% | -0.3% | +1.8% | +5.0% | +4.3% |
| Dec 23 | Roth Capital | Maintains | Buy → Buy | — | $67.03 | $67.81 | +1.2% | +0.4% | -2.4% | -1.1% | +0.8% | -0.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Reardon AndrewOff | CLO & Secretary | Sell | 800 | $234.02 | $187K | 41,382 | +1.73% | — |
| May 1, 2026 | Reardon AndrewOff | CLO & Secretary | Sell | 1,420 | $232.92 | $331K | 42,182 | +1.73% | — |
| May 1, 2026 | Reardon AndrewOff | CLO & Secretary | Sell | 780 | $232.04 | $181K | 43,602 | +1.73% | — |
| May 1, 2026 | Reardon AndrewOff | CLO & Secretary | Sell | 370 | $230.87 | $85K | 44,382 | +1.73% | — |
| May 1, 2026 | Reardon AndrewOff | CLO & Secretary | Sell | 98 | $229.71 | $23K | 44,752 | +1.73% | — |
| May 1, 2026 | Reardon AndrewOff | CLO & Secretary | Sell | 932 | $228.75 | $213K | 44,850 | +1.73% | — |
| May 1, 2026 | Reardon AndrewOff | CLO & Secretary | Sell | 600 | $227.45 | $136K | 45,782 | +1.73% | — |
8-K · 2.02
!! High
Ligand Pharmaceuticals Incorporated -- 8-K 2.02: Earnings Results
Ligand Pharmaceuticals reported Q1 2026 financial results, providing investors updated performance metrics and operational insights for assessing the company's financial health and strategic progress.
May 7
8-K · 1.02
!! High
Ligand Pharmaceuticals Incorporated -- 8-K 1.02: Material Agreement Terminated
The TR-Beta Program license termination with Valley Blvd effective May 4, 2026 removes a development partnership, though the filing doesn't specify whether this was mutual, breach-based, or regulatory-driven—investors should clarify the reason's impact on the company's pipeline.
Apr 30
8-K
XOMA ROYALTY CORP - XOMA 8 5/8 PERP -- 8-K Filing
Legendarily XOMA Royalty shareholders will receive cash and contingent value rights tied to RemainCo LLC interests in the merger, providing potential future payments beyond immediate consideration.
Apr 27
8-K
LIGAND PHARMA-GENERAL CVR -- 8-K Filing
Ligand Pharmaceuticals shareholders will receive cash plus contingent value rights tied to RemainCo LLC's future performance under the merger agreement's CVR structure.
Apr 27
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The CFO's departure effective April 10, 2026 signals potential financial uncertainty or strategic shifts at Ligand Pharmaceuticals and Path Therapeutics, requiring investors to monitor interim leadership decisions and financial guidance updates closely.
Apr 10
8-K
Unknown — 8-K Filing
Repricing underwater stock options for 2.4 million shares avoids immediate dilution but signals weak equity performance and may frustrate existing shareholders who see compensation costs shifted rather than eliminated.
Apr 3
8-K
Ligand Pharmaceuticals Inc. -- 8-K Filing
Ligand Pharmaceuticals delivered 48% royalty revenue growth in 2025 while maintaining 2026 guidance of $245-$285 million in revenues and $8.00-$9.00 adjusted EPS, signaling confidence in sustained profitability.
Feb 26
Data updated apr 25, 2026 7:03pm
· Source: massive.com